» Articles » PMID: 30653341

Hepatic Transcriptome Signatures in Patients with Varying Degrees of Nonalcoholic Fatty Liver Disease Compared with Healthy Normal-weight Individuals

Abstract

Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of conditions ranging from simple steatosis (NAFL), over nonalcoholic steatohepatitis (NASH) with or without fibrosis, to cirrhosis with end-stage disease. The hepatic molecular events underlying the development of NAFLD and transition to NASH are poorly understood. The present study aimed to determine hepatic transcriptome dynamics in patients with NAFL or NASH compared with healthy normal-weight and obese individuals. RNA sequencing and quantitative histomorphometry of liver fat, inflammation and fibrosis were performed on liver biopsies obtained from healthy normal-weight ( n = 14) and obese ( n = 12) individuals, NAFL ( n = 15) and NASH ( n = 16) patients. Normal-weight and obese subjects showed normal liver histology and comparable gene expression profiles. Liver transcriptome signatures were largely overlapping in NAFL and NASH patients, however, clearly separated from healthy normal-weight and obese controls. Most marked pathway perturbations identified in both NAFL and NASH were associated with markers of lipid metabolism, immunomodulation, extracellular matrix remodeling, and cell cycle control. Interestingly, NASH patients with positive Sonic hedgehog hepatocyte staining showed distinct transcriptome and histomorphometric changes compared with NAFL. In conclusion, application of immunohistochemical markers of hepatocyte injury may serve as a more objective tool for distinguishing NASH from NAFL, facilitating improved resolution of hepatic molecular changes associated with progression of NAFLD. NEW & NOTEWORTHY Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in Western countries. NAFLD is associated with the metabolic syndrome and can progress to the more serious form, nonalcoholic steatohepatitis (NASH), and ultimately lead to irreversible liver damage. Using gold standard molecular and histological techniques, this study demonstrates that the currently used diagnostic tools are problematic for differentiating mild NAFLD from NASH and emphasizes the marked need for developing improved histological markers of NAFLD progression.

Citing Articles

Unraveling Metabolic Dysfunction-Associated Steatotic Liver Disease Through the Use of Omics Technologies.

Bourganou M, Chondrogianni M, Kyrou I, Flessa C, Chatzigeorgiou A, Oikonomou E Int J Mol Sci. 2025; 26(4).

PMID: 40004054 PMC: 11855544. DOI: 10.3390/ijms26041589.


A multi-omic landscape of steatosis-to-NASH progression.

Xiang L, Li X, Luo Y, Zhou B, Liu Y, Li Y Life Metab. 2025; 1(3):242-257.

PMID: 39872077 PMC: 11749464. DOI: 10.1093/lifemeta/loac034.


Pellino 3 E3 ligase promotes starvation-induced autophagy to prevent hepatic steatosis.

Kolapalli S, Beese C, Reid S, Brynjolfsdottir S, Jorgensen M, Jain A Sci Adv. 2025; 11(3):eadr2450.

PMID: 39823344 PMC: 11740972. DOI: 10.1126/sciadv.adr2450.


Complement 3a receptor 1 on macrophages and Kupffer cells is not required for the pathogenesis of metabolic dysfunction-associated steatotic liver disease.

Homan E, Gilani A, Rubio-Navarro A, Johnson M, Schaepkens O, Cortada E Elife. 2025; 13.

PMID: 39773465 PMC: 11709426. DOI: 10.7554/eLife.100708.


Identification and validation of efferocytosis-related biomarkers for the diagnosis of metabolic dysfunction-associated steatohepatitis based on bioinformatics analysis and machine learning.

Cao C, Liu W, Guo X, Weng S, Chen Y, Luo Y Front Immunol. 2024; 15:1460431.

PMID: 39497821 PMC: 11532026. DOI: 10.3389/fimmu.2024.1460431.